On Nov. 21, 2025, Robert J. More, Director of Tyra Biosciences (TYRA +1.89%), executed an open-market sale of 246,871 shares; see the SEC Form 4 filing for details.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 246,871 |
| Transaction value | $5.0 million |
| Post-transaction shares | 3,833,425 |
| Post-transaction value (direct ownership) | $77.6 million |
Transaction value based on SEC Form 4 reported price ($20.25).
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $1.352 billion |
| Price (as of market close 11/21/25) | $20.25 |
| Net income (TTM) | -$111.68 million |
| 1-year price change | 37.5% |
* 1-year performance calculated using November 21, 2025 as the reference date.
Company snapshot
- Develops targeted therapies for cancer and genetic diseases, with a lead candidate (TYRA-300) focused on FGFR3-driven muscle invasive bladder cancer and a pipeline addressing FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-related achondroplasia, FGFR4-related cancers, and RET (REarranged during transfection kinase)-driven conditions.
- Operates a preclinical-stage biotechnology model, leveraging proprietary SNAP platform technology to accelerate drug discovery and development; revenue generation is anticipated from future product approvals and commercialization.
- Targets oncologists, healthcare providers, and patients affected by cancers and genetic disorders involving fibroblast growth factor receptor pathways.
Tyra Biosciences is a biotechnology company specializing in precision oncology and rare genetic disease therapeutics, utilizing structure-based drug design to address resistance mechanisms in cancer treatment. The company's strategic focus on FGFR-driven diseases positions it to address unmet medical needs with differentiated small molecule therapies. Its proprietary SNAP platform enables rapid iteration and optimization, supporting a competitive edge in early-stage drug discovery.
NASDAQ: TYRA
Key Data Points
Foolish take
Director Robert More's $5 million share sale in November was part of a Rule 10b5-1 trading plan and does not indicate any change in conviction in the part of the insider. More still retains nearly 4 million shares of the biotech company, in fact, valued at current prices around $77.6 million.
The stock is up more than 80% year to date as of Dec. 23, trouncing the S&P 500's impressive total return of 18.4% over the same period. It announced its third-quarter financial results in early November, before More's recent share transaction. In it, the company reported slightly higher research and development (R&D) and selling, general, and administrative (SG&A) expenses as well as a slightly higher net loss over the year-ago period.
In December, the company announced two new appointments to the management team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer.
Wall Street analysts forecast significant upside potential for the stock, generally rating Tyra a moderate buy or buy. However, the biotech company is early-stage and doesn't generate any revenue, which makes it an inherently risky investment.
Glossary
Open-market sale: The sale of securities on a public exchange, available to any investor, at prevailing market prices.
Director: A member of a company's board responsible for overseeing management and major decisions.
Form 4: A required SEC filing disclosing insider trades by company officers, directors, or significant shareholders.
Insider trading: Buying or selling a company's securities by individuals with access to non-public, material information.
Disposition: The act of selling or otherwise transferring ownership of an asset or security.
Administrative transaction: A securities transaction not involving a change in beneficial ownership, such as a grant or award.
Preclinical-stage: The phase of drug development before testing in humans, focused on laboratory and animal studies.
SNAP platform: Tyra Biosciences' proprietary technology for accelerating drug discovery and optimization.
FGFR: Fibroblast growth factor receptor, a protein involved in cell growth and implicated in certain cancers and genetic diseases.
RET (REarranged during transfection kinase): A gene that can drive cancer growth when mutated or abnormally activated.
Structure-based drug design: Creating new drugs by analyzing the three-dimensional structure of biological targets.
TTM: The 12-month period ending with the most recent quarterly report.
